Evidence map›Paper›PMID 42074097›Full record

ReviewInternational journal of molecular sciences2026

Targeting DYRKs in Cardiovascular Diseases: From Biological Mechanisms to Therapeutic Translation.

Long Jiang, Siyu Peng, Junchen Ma, Tingfei Liu, Xiaoru Long, Lin Li, Huaying Wu

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Long JiangKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
Siyu PengKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
Junchen MaKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
Tingfei LiuKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
Xiaoru LongKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
Lin LiKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
Huaying WuKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.

Funding

National Natural Science Foundation of China No. 82405355National Students' Platform for Innovation and Entrepreneuship Training Program S202410542095, 202510542104Postgraduate Innovation Project of Hunan Province CX20250804
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, characterized by myocardial injury, pathological structural remodeling, and progressive deterioration of cardiac function. Clinical manifestations include post-infarct functional impairment, pathological cardiac hypertrophy, interstitial fibrosis, malignant arrhythmias, and end-stage heart failure. Although the dual-specificity tyrosine-regulated kinase (DYRK) family has been extensively investigated in cancer and neurodegenerative disorders, emerging evidence highlights DYRKs as critical upstream regulators in a wide spectrum of cardiovascular pathological processes. However, current research is largely confined to individual isoforms or isolated signaling pathways, lacking systematic integration of isoform-specific functions, dose- and spatiotemporal-dependent effects, as well as bidirectional regulatory roles in chronic cardiac remodeling. This review systematically summarizes the molecular mechanisms of the DYRK family across major cardiovascular disease models, with particular emphasis on the functional specificity of distinct DYRK isoforms and their translational potential as therapeutic targets. We further provide an integrated theoretical framework to facilitate the development of isoform-selective, context-dependent precision therapies for cardiovascular diseases.

Indexed as

Cardiovascular DiseasesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesAnimalsDyrk KinasesHumansMolecular Targeted TherapySignal TransductionTranslational Research, BiomedicalDyrk KinasesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine Kinasescardiac fibrosisDYRKsheart failurekinase inhibitorsmyocardial infarctiontherapeutic translation

Identifiers

PMID42074097
PMCPMC13116966

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.